Home
Scholarly Works
A phase I study of BI 853520, an inhibitor of...
Conference

A phase I study of BI 853520, an inhibitor of focal adhesion kinase (FAK), in patients with advanced or metastatic solid tumors.

Authors

Zer A; Verheijen R; De Vos FYFL; Hotte S; Eskens F; Pronk L; Siu LL; Schnell D; Steeghs N; Langenberg MH

Volume

33

Pagination

pp. 2541-2541

Publisher

American Society of Clinical Oncology (ASCO)

Publication Date

May 20, 2015

DOI

10.1200/jco.2015.33.15_suppl.2541

Conference proceedings

Journal of Clinical Oncology

Issue

15_suppl

ISSN

0732-183X
View published work (Non-McMaster Users)

Contact the Experts team